Dejerine–Sottas disease

From WikiMD's Food, Medicine & Wellness Encyclopedia

(Redirected from Dejerine-Sottas disease)

Dejerine-Sottas Syndrome

Dejerine–Sottas disease (DSD), also known as hereditary motor and sensory neuropathy type III (HMSN III) or Dejerine–Sottas neuropathy, is a rare genetic disorder that affects the peripheral nervous system. It is characterized by progressive muscle weakness and sensory loss, primarily in the extremities.

History[edit | edit source]

Dejerine–Sottas disease was first described by Joseph Jules Dejerine and Jules Sottas in 1893. The condition is named after these two French neurologists who identified the disease based on its clinical and pathological features.

Genetics[edit | edit source]

Dejerine–Sottas disease is typically inherited in an autosomal recessive manner, although some cases may follow an autosomal dominant pattern. Mutations in several genes, including PMP22, MPZ, EGR2, and PRX, have been associated with the disease. These genes are involved in the development and maintenance of myelin, the protective sheath surrounding nerve fibers.

Pathophysiology[edit | edit source]

The primary pathological feature of Dejerine–Sottas disease is the abnormal development and maintenance of myelin, leading to demyelination and subsequent axonal loss. This results in impaired nerve conduction and the clinical manifestations of the disease.

Clinical Features[edit | edit source]

Patients with Dejerine–Sottas disease typically present in early childhood with symptoms such as:

Diagnosis[edit | edit source]

The diagnosis of Dejerine–Sottas disease is based on clinical evaluation, family history, and genetic testing. Nerve conduction studies and electromyography (EMG) can help assess the extent of nerve damage. Nerve biopsy may show characteristic features such as onion bulb formations due to repeated cycles of demyelination and remyelination.

Treatment[edit | edit source]

There is currently no cure for Dejerine–Sottas disease. Treatment is primarily supportive and focuses on managing symptoms and improving quality of life. This may include:

Prognosis[edit | edit source]

The progression of Dejerine–Sottas disease varies among individuals. Some patients may experience a relatively mild course, while others may develop significant disability. Early intervention and supportive care can help manage symptoms and improve outcomes.

Related Pages[edit | edit source]

See Also[edit | edit source]

References[edit | edit source]

External Links[edit | edit source]


Wiki.png

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD


Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD

WikiMD is not a substitute for professional medical advice. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.

Contributors: Prab R. Tumpati, MD